ferred tax liabilities 59,358 58,554 8,573
Other liabilities 20,529 20,999 3,074
Total liabilities 476,900 572,598 83,834
Equity
Simcere shareholders' equity
Ordinary shares at par 9,624 8,987 1,316
Additional paid-in capital 1,505,252 1,269,793 185,909
Accumulated other comprehensive loss (82,130) (56,476) (8,269)
Retained earnings 820,279 905,693 132,601
Total Simcere shareholders' equity 2,253,025 2,127,997 311,557
Noncontrolling interest 48,297 52,186 7,640
Total equity 2,301,322 2,180,183 319,197
Commitments and contingencies
Total liabilities and equity 2,778,222 2,752,781 403,031
Note: The conversions of Renminbi (RMB) into United States dollars (USD)
as at the reporting dates are based on the noon buying rate of
USD1.00 = RMB6.8302 on June 30, 2009 as set forth in the H. 10
statistical release of the Federal Reserve Board. No representation
is intended to imply that the RMB amounts could have been, or could
be, converted, realized or settled into U.S. dollars at that rate on
the reporting dates.
For further information, please contact:
In Nanjing:
Simcere Pharmaceutical Group
Frank Zhao
Chief Financial Officer
Tel: +86-25-8556-6666 ext. 8818
Email:
ir@simcere.com
In the United States:
Brunswick Group LLC
Kate Tellier
Tel: +1-212-333-3810
In Beijing:
Brunswick Group LLC
Ruirui Jiang
Tel: +86-10-6566-2256
In Hong Kong:
Brunswick Group LLC
Joseph Lo Chi-Lun
Tel:
'/>"/>SOURCE Simcere Pharmaceutical Group Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine news :1.
Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.2.
Simcere Pharmaceutical Group Reports Third Quarter 2007 Results3.
Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 20084.
Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results5.
Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China6.
Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 20087.
Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.8.
Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin9.
Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results10.
Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 200811.
Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir